a little johnson & johnson story, page-10

Hi Martin,

Whilst OBJ's three separate technology platforms, as you say are not "microneedles", we must also remember that they are not transdermal patches either.

They are technology platforms designed for a large number of applications for enhancing the performance across a broad range of medical, consumer, household and industrial products.

You'll find most of my posts can be long winded and repetitive in attempt to paint a full picture (from my perspective) for all readers. The execution may not always be successful and for all I know it may only serve to confuse those new to OBJ, whilst undoubtedly boring the crap out of the regulars - but this continues to be a work in progress until OBJ blossoms.

Whether this represents competition or a connection to OBJ, I believe it remains of equal importance for all investors to know what's going on round the world.
Tomorrow's successful business is today's innovation collaborators, and I sleep very well at night with the knowledge that OBJ are working in a multidisciplinary environment collaborating with some of the world's largest, most innovative and competitive giants on this planet - It really doesn't leave much room to fear competition, imo.

"interesting enough to warrant checking it out" is exactly what I'm trying to encourage, so I appreciate, in this instance that I have been successful with you, Martin. And fyi i'll add the following points which I think are important to take away from the title post:

All "emphasized" text with quotation marks below have been extracted from reliable and validated company sources, ie OBJ website, OBJ announcements, Zosano website, Zosano announcements, etc...

- "OBJ provides partnering services in the creation of next generation Transdermal, Intra-Dermal (ie micro-needle) and applicator products..."

- "OBJ operates as a technology partner providing IP opportunities and market exclusivity..."

- "Alza Corp which was founded in the 1970's pioneered the field of drug delivery systems, bringing over 20 prescription pharmaceutical products to market, and employing about 10,000 people during 20 years until it was acquired by Johnson & Johnson in 2001, in a deal worth US$10.5 billion"

- "In October 2006 Macroflux Corp was created as a new transdermal drug development spin-off company out of Alza Corp."

- "In November 2006 OBJ announced the development of the first power-less active drug patch technology incorporating new techniques to drive larger and more complex molecules through the skin. The result is a novel biphasic material which captures thermal energy from the body."

biphasic:
1. having two phases
2. (Engineering / Electrical Engineering)
two-phase:
(Engineering / Electrical Engineering) (of an electrical circuit, device, etc.) generating or using two alternating voltages of the same frequency, displaced in phase by 90°

- "In January 2007 OBJ announced the engagement of former-Executive Director of ALZA Corporation, Dr Ravi Kiron PhD, MBA, to advise OBJ on a consultancy basis and to assist the growth of its transdermal drug delivery products and licensing business. Dr Kiron was responsible for bringing in external complementary and innovative technologies to enhance ALZA’s own internal R&D delivery efforts. Dr Kiron was first introduced to OBJ’s novel non-contact drug delivery technology at the Drug Delivery and Licensing Conference in Singapore in June 2006."

- "In September 2007 Macroflux Announces Name Change to Zosano Pharma, Inc."

- "In December 2007 OBJ executes a new research collaboration agreement with a global healthcare company"

- "In October 2008 OBJ announces the execution of a second research collaboration agreement with the same FMCG company to evaluate and optimise its proprietary DP and ETP drug delivery platforms"

- "In October 2009 OBJ advises that it has received the final report of a US Study covering the Company’s research collaboration with a FMCG company. The study tested the performance of OBJ’s technologies in a fully formulated patch format, when compared to an existing product with significant international sales."

- "In November 2009 Zosano Pharma, announced the Publication of Positive Phase 2 Study of its ZP-PTH Patch
which concluded that daily administration of the ZP-PTH resulted in a statistically significant performance over both placebo and FORTEO®."

- "In Nov 2009 OBJ enters into a Materials Transfer Agreement with 3M Corporation of St Paul, Minnesota USA"

- "In December 2009 the Springerlink science journal received clinical study data for Zosano's ZP-PTH microneedle patch system which stated that the statistical methods were best described by a one-compartment disposition model with a biphasic slow and fast first-order absorption process for the ZP-PTH patch applications. Based on encouraging Phase 2 safety and efficacy data, the program is advancing into a pivotal Phase 3 clinical study. The microneedle array is attached to an adhesive patch (Medical Tape 1523, 3M, St Paul, MN)"

- "In April 2010 OBJ released a statement in regards to the MTA with 3M stating that after the broadening of the testing program following the completion of the earlier initial phase, OBJ and 3M agreed to extend the testing with OBJ’s partners and that due to pre-existing clinical program commitments at 3M Drug Delivery Systems facility OBJ and 3M agreed to a further 6 month extension of the MTA."

Coincidentally or not there is no more News or Press Releases from Zosano relating to these developments between November 2009 and October 2011, with the exception of a presentation at The 14Th Annual Drug Delivery Partnerships Meeting in January 2010. In conjunction with this information I also encourage you to refer back to some of the much earlier OBJ releases like the Investor Presentation & Update released to the market on 19/06/2007 which may provide further clues.

The following information is also provided on the Zosano website

Partnering
Zosano's efficient drug delivery platform generates more commercial opportunities than we can pursue independently. Strategic partnering is therefore a critical component of our ability to advance Zosano's novel therapeutics programs into clinical development and onto the market.

Zosano’s objective is to selectively partner at strategic stages of the development process while retaining select therapeutic programs to develop independently. We want to strategically integrate our proprietary transdermal technology platform into the best possible companies to insure we achieve the most rapid development of therapeutics which utilize our base technology. This strategy will enable the Company to maximize the number of lead compounds it can rapidly put into development as it continues to harvest output and develop its platform to a higher degree of productivity.

Zosano pursues the following types of collaborations:
Licensing and/or co-development arrangements for our clinical pipeline products and pre-clinical drugs in development. Zosano can collaborate to develop therapeutics from our existing programs of both proteins/peptides and small molecules. Partners may choose to advance these programs independently or in conjunction with Zosano.

Partners may also work with Zosano to augment their own pipelines by utilizing our propriety transdermal delivery technology in conjunction with the partner’s products. Thereby insuring long term life cycle management for critical internal programs

Our goal is to be the partner of choice in providing the most rapid, efficient and cost effective pathway for developing high quality transdermal delivered therapeutics to treat serious health conditions. Zosano brings a full range of capabilities to the drug delivery development and manufacturing process, making the company the ideal partner for many of the industry’s leading pharmaceutical and biotechnology companies